Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily, with titration based on clinical response. Doses may be increased up to 240 mg intravenously daily (divided into 3 doses) or 160 mg orally daily.
## Pediatric Dosing
Dosing in pediatric patients varies by indication and age/weight. Consult specific pediatric guidelines or product labeling for appropriate dosing.
* **Children 5 to 16 years of age:**
* Erosive esophagitis: 40 mg orally once daily.
* GERD symptoms: 20 mg orally once daily.
* **Children younger than 5 years:** Safety and efficacy not established.
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment, although caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of fractures, Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors.
* **Methotrexate:** Co-administration may increase methotrexate levels.
* **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19, potentially affecting the metabolism of drugs such as clopidogrel.
## Monitoring
* Monitor for signs and symptoms of fractures, C. difficile infection, and hypomagnesemia, especially with long-term use.
* Monitor for efficacy in symptom relief.
## Clinical Pearls
* Administer pantoprazole delayed-release tablets 30 minutes before a meal.
* Intravenous administration is an option when oral route is not feasible.
* Long-term use should be regularly re-evaluated for continued need.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for definitive drug recommendations and patient management.*
